Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BVS NYSE:CATX NYSE:CMD NASDAQ:HSAQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$6.57+2.7%$6.67$6.02▼$14.38$539.69M0.84377,186 shs263,888 shsCATXPerspective Therapeutics$4.06-2.2%$3.40$1.60▼$16.55$301.37M1.18979,910 shs784,237 shsCMDCantel Medical$80.37$82.48$39.40▼$89.76$3.58B1.55626,604 shsN/AHSAQHealth Sciences Acquisitions Co. 2$3.22+0.9%$3.02$9.41▼$13.80$36.10M0.09205,918 shs81,837 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus-1.08%-1.39%-5.33%-16.34%-14.21%CATXPerspective Therapeutics-4.60%+0.48%+8.64%+73.64%-67.50%CMDCantel Medical0.00%0.00%0.00%0.00%0.00%HSAQHealth Sciences Acquisitions Co. 20.00%+9.59%+3.23%+24.03%-60.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBVSBioventus3.3644 of 5 stars3.40.00.00.03.23.31.3CATXPerspective Therapeutics2.3736 of 5 stars4.61.00.00.02.20.80.0CMDCantel Medical1.3955 of 5 stars0.00.01.74.10.62.50.6HSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 2.75Moderate Buy$13.75109.28% UpsideCATXPerspective Therapeutics 3.18Buy$12.56209.25% UpsideCMDCantel Medical 0.00N/AN/AN/AHSAQHealth Sciences Acquisitions Co. 2 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CMD, BVS, CATX, and HSAQ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/12/2025CATXPerspective TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/7/2025BVSBioventusCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$12.006/23/2025CATXPerspective TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $12.006/23/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.006/3/2025CATXPerspective TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.005/14/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.005/13/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.005/7/2025BVSBioventusCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$15.00(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$567.70M0.95$0.52 per share12.58$2.80 per share2.35CATXPerspective TherapeuticsN/AN/AN/AN/A$2.67 per shareN/ACMDCantel Medical$1.02B3.52$3.38 per share23.78$17.31 per share4.64HSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/A($0.62) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus-$156.23M-$0.48N/A14.28N/A-7.11%15.61%4.01%N/ACATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/13/2025 (Estimated)CMDCantel Medical$13.71M$1.6569.2828.911.634.72%12.13%4.45%N/AHSAQHealth Sciences Acquisitions Co. 2-$380KN/A0.00∞N/AN/AN/A-2.38%N/ALatest CMD, BVS, CATX, and HSAQ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025N/ACATXPerspective Therapeutics-$0.30N/AN/AN/A$0.17 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/ACATXPerspective TherapeuticsN/AN/AN/AN/AN/ACMDCantel Medical$0.210.26%N/A12.73%N/AHSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.851.410.99CATXPerspective TherapeuticsN/A9.609.60CMDCantel Medical1.162.722.00HSAQHealth Sciences Acquisitions Co. 2N/A0.170.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%CATXPerspective Therapeutics54.66%CMDCantel Medical84.13%HSAQHealth Sciences Acquisitions Co. 289.71%Insider OwnershipCompanyInsider OwnershipBVSBioventus33.00%CATXPerspective Therapeutics3.72%CMDCantel Medical10.70%HSAQHealth Sciences Acquisitions Co. 221.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20082.14 million54.46 millionNot OptionableCATXPerspective Therapeutics7074.23 million65.21 millionOptionableCMDCantel Medical3,66944.51 millionN/AOptionableHSAQHealth Sciences Acquisitions Co. 2411.21 million8.76 millionNot OptionableCMD, BVS, CATX, and HSAQ HeadlinesRecent News About These CompaniesCardinal Health inks 2 acquisitions worth $3.9BNovember 14, 2024 | healthcaredive.comHCardinal Health expands gastroenterology, diabetes businesses with two deals worth $3.9 billionNovember 12, 2024 | msn.comAnalysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Exact Sciences (EXAS) and Crispr Therapeutics AG (CRSP)November 6, 2024 | markets.businessinsider.comHealthStream acquires two companies for combined $2.2MNovember 6, 2024 | nashvillepost.comNHealthStream acquires two companies for combined $2.2 millionNovember 6, 2024 | nashvillepost.comNHealth companies backed by private-equity firms have 900 locations in the Philadelphia regionOctober 30, 2024 | inquirer.comIExact Sciences Corporation (EXAS): A Buzzing AI Health Stock to Add to Your PortfolioOctober 5, 2024 | msn.comWaud Capital snaps up health tech firm Science ExchangeOctober 1, 2024 | pehub.comHartford HealthCare seeks approval to take control of 2 surgical center operatorsSeptember 27, 2024 | hartfordbusiness.comHAcquisitions work as a one-time efficiency boost for hospital margins: studySeptember 27, 2024 | healthcaredive.comHUS healthtech company Syra closes $2.1m public offeringSeptember 16, 2024 | msn.comHealth plan performance dips on NCQA’s equity measuresSeptember 16, 2024 | modernhealthcare.comMQuest Completes Acquisition Of Select Laboratory Assets From Allina HealthSeptember 16, 2024 | markets.businessinsider.comRisant's Cone Health acquisition: 3 new detailsAugust 28, 2024 | beckershospitalreview.comBEarnings call: CV Sciences maintains revenue, eyes growth with acquisitionsAugust 15, 2024 | investing.comCommunity Health Systems, Inc. (CYH) Q2 2024 Earnings Call TranscriptJuly 25, 2024 | seekingalpha.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Healthequity (HQY), Community Health (CYH) and Gilead Sciences (GILD)July 25, 2024 | markets.businessinsider.comHealthcare & Life Sciences Private Equity Deal Tracker: Hamilton Lane Acquires Stake in Avista-Backed Cosette PharmaceuticalsJuly 22, 2024 | jdsupra.comBiogen joins immunology wave with $1.15 billion acquisitionMay 22, 2024 | statnews.comSHealthEquity Closes Conduent's BenefitWallet AcquisitionMay 17, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMD, BVS, CATX, and HSAQ Company DescriptionsBioventus NYSE:BVS$6.57 +0.17 (+2.66%) Closing price 04:00 PM EasternExtended Trading$6.49 -0.08 (-1.22%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Perspective Therapeutics NYSE:CATX$4.06 -0.09 (-2.17%) Closing price 04:00 PM EasternExtended Trading$4.00 -0.06 (-1.58%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Cantel Medical NYSE:CMDCantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Medical segment offers automated endoscope reprocessing systems; disinfectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets and transport systems; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services. Its Life Sciences segment provides dialysis water purification and bicarbonate mixing systems; hollow fiber filters, and other filtration and separation products; liquid disinfectants and cold sterilization products; dry fog products; room temperature sterilization equipment and services; and clean-room certification and decontamination services for the dialysis and other healthcare, research laboratories, food and beverage, and commercial industrial customers, as well as microbiological testing services. The company's Dental segment offers hand and powered dental instruments, instrument reprocessing and sterility assurance products, towels, bibs, tray liners, sponges, nitrous oxide/oxygen sedation equipment and related single-use disposable nasal masks, face masks, and shields. It also provides hand sanitizers, germicidal wipes, disinfectants, surface disinfectants, waterline treatment products, saliva ejectors, evacuator tips, plastic cups, prophy angles, and prophy paste. The company's Dialysis segment provides hemodialysis concentrates and other ancillary supplies; medical device reprocessing systems; and sterilants and disinfectants. The company sells its products through its direct distribution network in the United States; and directly or under various third-party distribution agreements internationally. Cantel Medical Corp. was founded in 1963 and is headquartered in Little Falls, New Jersey.Health Sciences Acquisitions Co. 2 NASDAQ:HSAQ$3.22 +0.03 (+0.94%) As of 07/24/2025Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
